Dividend ETF's Heavyweights Deliver Divergent Results, Keeping Fund Near Record
Published on 08/05/2026 at 04:03 | Redaktion boerse-global.de
The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF is hovering within striking distance of its all-time high, thanks in large part to two of its largest holdings delivering earnings surprises in the same trading session. HSBC and Pfizer — cornerstones of the fund's financials and healthcare weightings — both reported on Tuesday, though for markedly different reasons.
The fund's shares last changed hands at €55.20, a mere 0.83 percent below the 52-week peak of €55.66 touched on August 4. Over the past twelve months, the ETF has gained 28.30 percent.
HSBC's Half-Year Momentum
The London-headquartered lender posted a first-half 2026 pretax profit of $19.5 billion, a 23 percent jump year-on-year. Revenue climbed 11 percent to $37.7 billion, propelled by higher net interest income and fee generation, though rising credit impairments and elevated operating costs took some of the edge off.
The quarterly breakdown is even more striking. Pretax earnings surged 60 percent to $10.1 billion versus the same period last year, while after-tax profit advanced 63 percent to $7.9 billion. A one-off gain of $2.6 billion from exceptional items provided a meaningful tailwind. Return on average tangible equity came in at 18.2 percent.
Management rewarded shareholders accordingly. A second interim dividend of $0.10 per share was approved, alongside a share buyback program of up to $1 billion slated for completion by the time third-quarter results are presented. Chief executive Georges Elhedery said the bank was executing its strategic priorities "with speed, precision and discipline," adding that HSBC is "getting stronger as we planned."
For income-focused investors, the more consequential detail concerns the payout ratio: HSBC has committed to maintaining its 50 percent distribution policy through 2027 and 2028, cementing its role as a reliable income generator within the fund's financials sleeve.
One blemish: the common equity Tier 1 ratio slipped 0.8 percentage points to 14.1 percent, partly reflecting the privatization of Hang Seng Bank.
Pfizer Beats on Revenue, Wrestles With Write-Down
Pfizer's second-quarter numbers told a more nuanced story. Revenue rose $381 million to $15.0 billion, a 3 percent improvement, and the company lifted the midpoint of its full-year sales guidance by $500 million. Adjusted earnings per share of $0.77 came in nine cents ahead of the $0.68 consensus, while adjusted profit of $4.44 billion was essentially flat against $4.43 billion a year earlier.
Yet the bottom line swung to a loss, dragged down by a non-cash impairment charge of $4.3 billion. The write-down followed disappointing late-stage trial data for the oncology drug Sigvotatug Vedotin in previously treated non-small cell lung cancer, prompting Pfizer to trim sales expectations for certain products.
The fading pandemic franchise continues to weigh as well. Combined 2026 guidance for Comirnaty and Paxlovid was cut to roughly $4 billion from an earlier estimate of around $5 billion. In response, the company sharpened its cost-cutting agenda, targeting an additional $2.5 billion in net savings between 2027 and 2029.
CEO Albert Bourla struck an upbeat tone nonetheless, citing strong performance across both in-house and acquired products, accelerating momentum in the obesity program, and an oncology portfolio that remains a core strength.
A Fund Built for Mixed Seasons
The juxtaposition of HSBC's profit surge and Pfizer's accounting-driven loss illustrates exactly the kind of dispersion the fund's construction is meant to absorb. The ETF screens for developed-market companies with long track records of reliable dividend payments, applies ESG filters, and charges a total expense ratio of 0.38 percent annually — positioning it among Europe's established global income vehicles.
The most recent distribution, paid June 10, 2026, came in at €0.81 per share, implying a forward dividend yield of 5.89 percent. Financials and healthcare currently represent the fund's largest sector weightings, and this week's reports offered a live demonstration of why that pairing has served investors well.
Versus competing products such as the Vanguard FTSE All-World High Dividend Yield ETF or the iShares STOXX Global Select Dividend 100, VanEck's approach leans on quality screening combined with broad sector diversification. The fund sits roughly 0.9 percent below its record, consolidating after Tuesday's fresh high — a level that, on a one-year view, still leaves holders with a gain of more than 28 percent.
Ad
VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock: New Analysis - 5 August
Fresh VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF analysis...
